Antipyretic TRIZ Cases
- Gap Junction Enhancing Agents for Intestinal Mucosal Healing
Gap junction enhancing agents increase enterocyte migration rate to restore intestinal mucosal barrier integrity.
- Adapalene Benzoyl Peroxide Gel for Acne Lesion Reduction
Merges adapalene and benzoyl peroxide into one fixed composition to resolve insufficient efficacy of monotherapies while maintaining skin tolerance.
- Targeting CK5+ Basal Cells to Prevent Prostate Cancer Recurrence
Combination therapies target CK5+ basal cells to prevent androgen-independent tumor progression.
- Thermoplastic Cellular Polymer Foam for Multi-Directional Crash Energy Absorption
Thermoplastic cellular polymer foam dissipates impact energy uniformly across multiple orthogonal directions without orientation constraints.
- Humanized Anti-IL-31 Antibody Reducing Immunogenicity
Humanized anti-IL-31 antibodies resolve immunogenicity and half-life trade-offs by grafting mouse CDRs onto human frameworks.
- Breast Hyperplasia Composition Using Plant Extracts
A herbal composition reduces breast hyperplasia symptoms through synergistic plant extracts.
- Natural Ointment Formulation for Rapid Pain Relief
A natural ointment combines coconut oil and plant extracts to deliver rapid pain relief on skin contact.
- AHR Agonists Modulate TLR4 Signaling to Prevent NEC
AHR agonists activate the aryl hydrocarbon receptor pathway to attenuate TLR4 signaling and prevent necrotizing enterocolitis in premature infants.
- Anti-TLR3 Antibodies Targeting N-Terminal Epitopes for Autoimmune Therapy
Engineered monoclonal antibodies target the TLR3 N-terminal domain to resolve low binding affinity and improve therapeutic efficacy in autoimmune diseases.
- Ex Vivo Neutrophil Production via Low Oxidative Stress Culture
Low-density seeding minimizes oxidative stress, enabling 5,000-fold neutrophil expansion while resolving viability and production time contradictions.
- Monoclonal Antibodies Targeting TLR4/MD-2 Complex
Segmented antibody design neutralizes TLR4/MD-2 activation, inhibiting LPS-induced cytokine production for treating immune disorders.
- Fluid Dispensing Device Pre-Load Mechanism for Viscous Medicament
A fluid dispensing device uses a pre-load mechanism to actuate a compression pump via a finger-operable lever.
- Curcumin L-Arginine Co-Crystals for Bioavailability
Solid curcumin-L-arginine compounds improve solubility to overcome poor bioavailability in anti-inflammatory treatments.
- Anti-P-selectin Antibodies with Non-Binding Fc Region
Mutating the Fc region prevents C1q binding and adverse effects, enhancing therapeutic efficacy for ischemia.
- GPR119 Agonists for Osteoporosis via GIP Pathway
GPR119 agonists bypass poor oral bioavailability of direct peptide therapy by activating receptors to boost GIP secretion and treat osteoporosis.
- CD22-Specific Antibodies for Selective B Cell Modulation
Segmenting B cell populations via CD22 targeting resolves the contradiction between reducing autoimmune events and preserving protective immunity.
- NI-0501 Anti-IFNγ Antibody for HLH Biomarker Diagnosis
NI-0501 neutralizes interferon gamma, reducing inflammation and toxicity in hemophagocytic lymphohistiocytosis patients.
- Single Effector Immunoconjugate Reduces Systemic Toxicity
Segmenting cytokine moieties into a single effector unit lowers receptor avidity, preventing systemic toxicity while maintaining tumor targeting.
- Anti-BDCA-2 Antibody Selective pDC Depletion
Targeting BDCA-2 depletes plasmacytoid dendritic cells to reduce inflammation without causing immunodeficiency.
- C5aR Antagonists for Rheumatoid Arthritis Bone Protection
Targeting the C5a receptor pathway with specific antibodies resolves the trade-off between reducing acute inflammation and preserving joint bone integrity.
- Species-Specific Monoclonal Antibodies for Companion Animal CD52 Treatment
Heterochimeric antibodies target canine, feline, and equine CD52 antigens to deplete leukocytes with reduced immunogenicity.